Clinical Trials Directory

Trials / Conditions / Acute Gout

Acute Gout

12 registered clinical trials studyying Acute Gout — 1 currently recruiting.

StatusTrialSponsorPhase
UnknownA Study of Recombinant Anti-IL-1β Humanized Monoclonal Antibody Injection in Chinese Participants With Acute G
NCT06169891
Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.Phase 3
CompletedSafety and Efficacy of Genakumab for Injection in Patients With Gout Flare
NCT05936268
Changchun GeneScience Pharmaceutical Co., Ltd.Phase 2
RecruitingPrednisolone Versus Colchicine for Acute Gout in Primary Care
NCT05698680
University Medicine GreifswaldPhase 4
UnknownA Phase Ib/II Study of Recombinant Anti-IL-1β Humanized Monoclonal Antibody Injection in Chinese Participants
NCT05588908
Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.Phase 1 / Phase 2
CompletedClinical Study of Genakumab for Injection in Patients With Acute Gout
NCT05328531
Changchun GeneScience Pharmaceutical Co., Ltd.Phase 1 / Phase 2
CompletedRecombinant Human Tumor Necrosis Factor-α Receptor Ⅱ Fusion Protein in the Treatment of Acute Gout
NCT05925166
Lihua DuanN/A
UnknownEfficacy and Safety of HuZhen Capsule for Treatment of Patients With Acute Gout
NCT02674776
Quan JiangPhase 3
WithdrawnApremilast Therapy for Acute Gouty Arthritis
NCT00997581
Dartmouth-Hitchcock Medical CenterPhase 2
CompletedCanakinumab in the Treatment of Acute Gout Flares and Prevention of New Flares in Patients Unable to Use Non-s
NCT01080131
Novartis PharmaceuticalsPhase 3
CompletedCanakinumab in the Treatment of Acute Gout Flares and Prevention of New Flares in Patients Unable to Use Non-s
NCT01029652
Novartis PharmaceuticalsPhase 3
CompletedTargeted Dose Finding of Canakinumab (ACZ885) for Management of Acute Flare in Refractory or Contraindicated G
NCT00798369
NovartisPhase 2
CompletedA Study Evaluating the Effect of Etoricoxib and Indomethacin in the Treatment of Acute Gout (0663-081)(COMPLET
NCT00142558
Organon and CoPhase 4